EFPIA boss damning on European pharma investment

Nathalie Moll, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), has expressed “deep concern” at a long-term trend of research and development activity moving to other regions.

In a column ahead of EFPIA’s publication of a new paper next week, she writes of the need for an infrastructure and policy environment that supports medical research in the European Union (EU).

The EFPIA paper, entitled An EU Industrial Strategy: An Opportunity to Drive Europe’s Health and Growth, will be launched alongside the European Commission’s (EC) publication of its Industrial Strategy and the roadmap for the upcoming Pharmaceutical Strategy.